Saturday - November 23, 2024
AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline at ASH 2024
November 08, 2024
WILMINGTON, Delaware, Nov. 8 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Nov. 7, 2024:

* * *

First results from AMPLIFY trial will reinforce CALQUENCE as leading second-generation BTK inhibitor in frontline chronic lymphocytic leukemia with fixed-duration regimen

Next generation cell therapy and T-cell engagers will demonstrate promising early results in multiple types of blood cancer

New, long-ter . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products